SteadyMed Ltd. (STDY) Analysts See $-0.19 EPS

August 9, 2018 - By Matthew Richard

SteadyMed Ltd. (NASDAQ:STDY) Logo

Analysts expect SteadyMed Ltd. (NASDAQ:STDY) to report $-0.19 EPS on August, 10.They anticipate $0.14 EPS change or 42.42 % from last quarter’s $-0.33 EPS. After having $-0.39 EPS previously, SteadyMed Ltd.’s analysts see -51.28 % EPS growth. The stock decreased 1.06% or $0.05 during the last trading session, reaching $4.65. About 59,424 shares traded. SteadyMed Ltd. (NASDAQ:STDY) has declined 34.29% since August 9, 2017 and is downtrending. It has underperformed by 46.86% the S&P500.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Coverage

Among 2 analysts covering Steadymed (NASDAQ:STDY), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Steadymed had 2 analyst reports since April 9, 2018 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $1500 target in Monday, April 9 report. The firm earned “Market Perform” rating on Tuesday, May 1 by JMP Securities.

SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical firm that focuses on the development and commercialization of drug product candidates for the treatment of orphan and other diseases with unmet parenteral delivery needs. The company has market cap of $123.81 million. The company's product candidates are enabled by its proprietary PatchPump, a discreet, pre-filled, water-resistant, and disposable parenteral drug administration technology. It currently has negative earnings. The Company’s lead drug product candidate is Trevyent, a development stage drug that combines PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue for treating pulmonary arterial hypertension.

More recent SteadyMed Ltd. (NASDAQ:STDY) news were published by: which released: “HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd.” on July 20, 2018. Also published the news titled: “SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics” on July 31, 2018.‘s news article titled: “United Therapeutics gets crucial green light for its flagship drug” with publication date: July 31, 2018 was also an interesting one.

SteadyMed Ltd. (NASDAQ:STDY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.